Superficial skin swabs

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Superficial skin swabs is one of 7 biologic programs targeting Netherton syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Netherton SyndromeActive, not recruiting

Netherton SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Netherton Syndrome

#DrugCompanyPhaseTrials

Elidel

BBausch Health Americas, Inc.

Spevigo

1 3

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 4

Humira

CCelltrion

Phase 2

1 5

Ds-2325a

Daiichi Sankyo

Phase 2

1 6

Stool Collect

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 7

Superficial skin swabs

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Recruiting

Netherton Syndrome

NCT07280091

Clinical

Trials by Indication[1]

Netherton syndrome1 trial

Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome

Recruiting·AAssistance Publique - Hôpitaux de Paris··NCT07280091·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Superficial skin swabs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Superficial skin swabs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Superficial skin swabs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Superficial skin swabs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Netherton syndrome1 trial

References

Drug Info

Quick Facts

Related News